ClinicalTrials.gg
Status unknownNCT01202396Updated Sep 15, 2010

The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis

An observational study in Pouchitis, sponsored by Maastricht University Medical Center. Status unknown at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-09-15.

Sponsored by Maastricht University Medical Center · Observational

The sponsor has not verified this record recently (last verified Sep 2010), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Pouchitis is a common complication following proctocolectomy with ileal pouch anal anastomosis (IPAA) in patients with ulcerative colitis (UC). It affects the quality of life and can become a chronic problem. The aetiology of pouchitis is not completely understood. A crucial role of the intestinal microbiota has been suggested, but no causative agent has been identified so far. Furthermore, the defensin expression and the epithelial integrity are altered in inflammatory bowel diseases and may play an important role in the development of intestinal inflammation. Therefore, it has been hypothesized that the interaction between an altered microbiota composition, a defective epithelial integrity and changes in innate defense parameters such as defensins has a pivotal role in the development of pouchitis in UC patients.

02

Conditions studied

  • Pouchitis

Keywords

  • pouch
  • pouchitis
  • ulcerative colitis
  • microbiota
  • defensins
  • epithelial integrity
03

In context

Pouchitis

50 studies on the registry are indexed under Pouchitis; 12 are open to participants now.

Browse Pouchitis studies →

Lead sponsor

Maastricht University Medical Center is the lead sponsor of 853 studies on the registry; 114 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients undergoing proctocolectomy with the construction of an ileal pouch anal anastomosis will be asked to participate in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with ulcerative colitis undergoing a total colectomy with IPAA for dependent disease, therapy- disease, colorectal cancer or severe dysplasia
  • 18-65 years of age

Exclusion criteria

Exclusion Criteria:

  • unable to give
  • pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • ulcerative colitis patients with a pouch

    * ulcerative colitis patients undergoing proctocolectomy with an ileal pouch anal anastomosis * comparing patients with versus those without pouchitis * no intervention

06

What researchers measure

Primary outcomes

  1. Differences in the intestinal microbiota composition between pouch patients with and without pouchitis

    A phylogenetic microarray will be used to characterize the luminal and mucosal microbiota composition (based on the SSU rRNA gene)of pouch patients with and without pouchitis. Anticipated results are the identification of specific bacterial profiles, genera and/or species dat are discriminating between subgroups.

    Time frame: 24 months.

Secondary outcomes

  1. The expression of defensins in the intestinal mucosa

    The mRNA expression levels of human alfa and beta-defensins in intestinal mucosal biopsies will be assessed by real time PCR

    Time frame: 24 months

  2. The intestinal permeability

    The epithelial integrity will be studied by the multiple sugar test to assess small intestinal and whole gut permeability.

    Time frame: 24 months.

  3. Inflammatory mediators

    Cytokine levels will be studied in serum and in intestinal biopsies. Furthermore, a histological evaluation and the MPO activity will be studied in these biopsies and calprotectin levels will be determined in 'fecal' sampels.

    Time frame: 24 months

  4. The expression of tight-junction associated proteins

    The intestinal tight junctions-associated proteins will be studied by immune staining of intestinal biopsies and mRNA levels in intestinal biopsies using real time PCR. Biopsies will be collected from standardised locations.

    Time frame: 24 months.

07

Study locations

1 site
  • Maastricht University Medical Center, div. Gastroenterology-Hepatology
    Maastricht, Limburg 6226AZ, Netherlands
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 15, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01202396
First posted
Sep 15, 2010
Start date
Nov 2010
Primary completion
Nov 2014 (estimated)
Completion
Nov 2015 (estimated)
Last update
Sep 15, 2010

Study contacts

D. Jonkers, PhD
Contact
d.jonkers@intmed.unimaas.nl
*31-43-3875021
M. Pierik, PhD MD
Contact
m.pierik@mumc.nl
*31-43-3875021
A. Masclee, Prof MD PhD
principal investigator · Maastricht University Medical Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion